Patents by Inventor Garnett Kelsoe

Garnett Kelsoe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOCLONAL ANTIBODIES FOR PREVENTION AND TREATMENT OF HERPES SIMPLEX VIRAL INFECTIONS
    Publication number: 20220162291
    Abstract: Provided are antibodies and antigen-binding fragments which bind to herpes simplex virus-2 (HSV-2), methods of use employing the antibodies and/or antigen-binding fragments, and pharmaceutical compositions comprising the antibodies and/or antigen-binding fragments.
    Type: Application
    Filed: March 19, 2020
    Publication date: May 26, 2022
    Inventors: Betsy C. HEROLD, Garnett KELSOE, Masayuki KURAOKA, Clare BURN, William R. Jacobs, Jr.
  • Methods to identify prime and boost immunogens for use in a B cell lineage-based vaccination protocol
    Patent number: 10835599
    Abstract: The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: November 17, 2020
    Assignees: DUKE UNIVERSITY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Barton F. Haynes, Garnett Kelsoe, Stephen Harrison, Thomas B. Kepler
  • B cell lineage based immunogen design with humanized animals
    Patent number: 10626168
    Abstract: Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: April 21, 2020
    Assignees: REGENERON PHARMACEUTICALS, INC., DUKE UNIVERSITY
    Inventors: Barton Haynes, Garnett Kelsoe, Israel Lowy, Aris I. Baras, Lynn MacDonald, John McWhirter, Cagan Gurer, Karolina A. Meagher, Andrew J. Murphy, George D. Yancopoulos
  • VACCINE
    Publication number: 20190167783
    Abstract: The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol.
    Type: Application
    Filed: October 9, 2018
    Publication date: June 6, 2019
    Inventors: Barton F. HAYNES, Garnett KELSOE, Stephen HARRISON, Thomas B. KEPLER
  • B CELL LINEAGE BASED IMMUNOGEN DESIGN WITH HUMANIZED ANIMALS
    Publication number: 20180298082
    Abstract: Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.
    Type: Application
    Filed: March 29, 2018
    Publication date: October 18, 2018
    Inventors: Barton Haynes, Garnett Kelsoe, Israel Lowy, Aris I. Baras, Lynn MacDonald, John McWhirter, Cagan Gurer, Karolina A. Meagher, Andrew J. Murphy, George D. Yancopoulos
  • GP120 immunogens and methods inducing neutralizing antibodies to human immunodeficiency virus
    Patent number: 10092638
    Abstract: The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: October 9, 2018
    Assignees: DUKE UNIVERSITY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Barton F. Haynes, Garnett Kelsoe, Stephen Harrison, Thomas B. Kepler
  • B cell lineage based immunogen design with humanized animals
    Patent number: 9963501
    Abstract: Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: May 8, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Barton Haynes, Garnett Kelsoe, Israel Lowy, Aris I. Baras, Lynn MacDonald, John McWhirter, Cagan Gurer, Karolina A. Meagher, Andrew J. Murphy, George D. Yancopoulos
  • COMPOSITIONS AND METHODS FOR TRANSIENT IMMUNE RESPONSE MODULATION DURING VACCINATION
    Publication number: 20170216426
    Abstract: In certain aspects the invention provides a selection of HIV-1 envelopes suitable for use as immunogens, and methods of using these immunogens to induce neutralizing antibodies. In certain embodiments, the immunogens are designed to trimerize. In other embodiments, the immunogenic compositions and methods comprise at least one agent for transient immune response modulation during vaccination.
    Type: Application
    Filed: September 28, 2015
    Publication date: August 3, 2017
    Inventors: Barton F. HAYNES, Garnett KELSOE, Masayuki KURAOKA, M. Anthony MOODY, Hua-Xin LIAO, Laurent VERKOCZY
  • METHOD OF INDUCING THE PRODUCTION OF PROTECTIVE ANTI-HIV-1 ANTIBODIES
    Publication number: 20160271244
    Abstract: The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method.
    Type: Application
    Filed: February 29, 2016
    Publication date: September 22, 2016
    Inventors: Barton F. Haynes, Hua-Xin Liao, Georgia Tomaras, Thomas B. Kepler, Kwan-Ki Hwang, S. Munir Alam, Yang Liu, T. Matt Holl, Guang Yang, Garnett Kelsoe, Mattia Bonsignori
  • Adjuvant
    Patent number: 8926995
    Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV-1) and, in particular, to a method of enhancing an immune response to an HIV-1 immunogen, and to compounds and compositions suitable for use in such a method.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: January 6, 2015
    Assignee: Duke University
    Inventors: Barton F. Haynes, Laurent Verkoczy, M. Anthony Moody, Matt T. Holl, Masayuki Kuraoka, Garnett Kelsoe
  • VACCINE
    Publication number: 20140341949
    Abstract: The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol.
    Type: Application
    Filed: October 3, 2012
    Publication date: November 20, 2014
    Applicants: DUKE UNIVERSITY, Children's Medical Center Corporation
    Inventors: Barton F. Haynes, Garnett Kelsoe, Stephen Harrison, Thomas B. Kepler
  • B CELL LINEAGE BASED IMMUNOGEN DESIGN WITH HUMANIZED ANIMALS
    Publication number: 20140221625
    Abstract: Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.
    Type: Application
    Filed: February 6, 2014
    Publication date: August 7, 2014
    Inventors: BARTON HAYNES, GARNETT KELSOE, ISRAEL LOWY, ARIS I. BARAS, LYNN MACDONALD, JOHN MCWHIRTER, CAGAN GURER, KAROLINA A. MEAGHER, ANDREW J. MURPHY, GEORGE D. YANCOPOULOS
  • ADJUVANT
    Publication number: 20130243850
    Abstract: The present invention relates, in general, to human immunodeficiency vims (HIV-1) and, in particular, to a method of enhancing an immune response to an HIV-1 immunogen, and to compounds and compositions suitable for use in such a method.
    Type: Application
    Filed: November 23, 2011
    Publication date: September 19, 2013
    Applicant: DUKE UNIVERSITY
    Inventors: Barton F. Haynes, Laurent Verkoczy, Anthony M. Moody, Matt T. Holl, Masayuki Kuraoka, Garnett Kelsoe
  • METHOD OF INDUCING THE PRODUCTION OF PROTECTIVE ANTI-HIV-1 ANTIBODIES
    Publication number: 20120321699
    Abstract: The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method.
    Type: Application
    Filed: February 25, 2011
    Publication date: December 20, 2012
    Inventors: Barton F. Haynes, Hua-Xin Liao, Georgia Tomaras, Thomas B. Kepler, Kwan-Ki Hwang, S.Munir Alam, Yang Liu, T. Matt Holl, Guang Yang, Garnett Kelsoe, Mattia Bonsignori